These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38529678)

  • 21. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
    Salgado Guerrero M; Londono Jimenez A; Dobrowolski C; Mowrey WB; Goilav B; Wang S; Broder A
    BMC Nephrol; 2020 Oct; 21(1):450. PubMed ID: 33115441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prednisone in lupus nephritis: how much is enough?
    Ruiz-Irastorza G; Danza A; Perales I; Villar I; Garcia M; Delgado S; Khamashta M
    Autoimmun Rev; 2014 Feb; 13(2):206-14. PubMed ID: 24189280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monophasic Disease Course in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    J Rheumatol; 2018 Aug; 45(8):1131-1135. PubMed ID: 29858240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus.
    Paredes-Ruiz D; Martin-Iglesias D; Ruiz-Irastorza G
    Expert Rev Clin Immunol; 2024 Apr; 20(4):359-373. PubMed ID: 38112074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
    Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
    Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
    Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
    Durcan L; Winegar DA; Connelly MA; Otvos JD; Magder LS; Petri M
    J Rheumatol; 2016 Apr; 43(4):745-50. PubMed ID: 26834214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort.
    Ugarte A; Garcia de Bustos A; Ruiz-Arruza I; Soto-Peleteiro A; Martin-Iglesias D; Gonzalez-Echavarri C; Ruiz-Irastorza G
    Rheumatology (Oxford); 2021 Dec; 61(1):249-257. PubMed ID: 33769455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
    Seo MR; Chae J; Kim YM; Cha HS; Choi SJ; Oh S; Roh CR
    Lupus; 2019 May; 28(6):722-730. PubMed ID: 30971164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
    Mok CC; Ho LY; Tse SM; Chan KL
    Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
    Fessler BJ; Alarcón GS; McGwin G; Roseman J; Bastian HM; Friedman AW; Baethge BA; Vilá L; Reveille JD;
    Arthritis Rheum; 2005 May; 52(5):1473-80. PubMed ID: 15880829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.
    Su L; Qi Z; Guan S; Wei L; Zhao Y
    Front Immunol; 2022; 13():978910. PubMed ID: 36238309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
    Burge DJ; Werth VP; Boackle SA; Posada J
    Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.